Hubbry Logo
HysterectomyHysterectomyMain
Open search
Hysterectomy
Community hub
Hysterectomy
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Hysterectomy
Hysterectomy
Hysterectomy
View on Wikipedia
from Wikipedia
Hysterectomy
Diagram showing what is removed with a radical hysterectomy
SpecialtyGynaecology
ICD-9-CM68.9
MeSHD007044
MedlinePlus002915

Hysterectomy is the surgical removal of the uterus and cervix. Supracervical hysterectomy refers to the removal of the uterus while the cervix is spared. These procedures may also involve removal of the ovaries (oophorectomy), fallopian tubes (salpingectomy), and other surrounding structures. The terms "partial" or "total" hysterectomy are lay terms that incorrectly describe the addition or omission of oophorectomy at the time of hysterectomy. These procedures are usually performed by a gynecologist. Removal of the uterus is a form of sterilization, rendering the patient unable to bear children (as does removal of ovaries and fallopian tubes) and has surgical risks as well as long-term effects, so the surgery is normally recommended only when other treatment options are not available or have failed. It is the second most commonly performed gynecological surgical procedure, after cesarean section, in the United States.[1] Nearly 68 percent were performed for conditions such as endometriosis, irregular bleeding, and uterine fibroids.[1] It is expected that the frequency of hysterectomies for non-malignant indications will continue to fall, given the development of alternative treatment options.[2]

Medical uses

[edit]
Hysterectomy

Hysterectomy is a major surgical procedure that has risks and benefits. It affects the hormonal balance and overall health of patients. Because of this, hysterectomy is normally recommended as a last resort after pharmaceutical or other surgical options have been exhausted to remedy certain intractable and severe uterine/reproductive system conditions. There may be other reasons for a hysterectomy to be requested. Such conditions and/or indications include, but are not limited to:[3]

  • Endometriosis: growth of the uterine lining outside the uterine cavity. This inappropriate tissue growth can lead to pain and bleeding.[4]
  • Adenomyosis: a form of endometriosis, where the uterine lining has grown into and sometimes through the uterine wall musculature. This can thicken the uterine walls and also contribute to pain and bleeding.[5]
  • Heavy menstrual bleeding: irregular or excessive menstrual bleeding for greater than a week. It can disturb the regular quality of life and may be indicative of a more serious condition.
  • Uterine fibroids: benign growths on the uterus wall. These muscular noncancerous tumors can grow in single form or in clusters and can cause extreme pain and bleeding.[6]
  • Uterine prolapse: when the uterus sags down due to weakened or stretched pelvic floor muscles potentially causing the uterus to protrude out of the vagina in more severe cases.
  • Reproductive system cancer prevention: especially if there is a strong family history of reproductive system cancers (especially breast cancer in conjunction with BRCA1 or BRCA2 mutation), or as part of recovery from such cancers.[7]
  • Gynecologic cancer: depending on the type of hysterectomy, can aid in the treatment of cancer or precancer of the endometrium, cervix, or uterus. To protect against or treat cancer of the ovaries, one would need an oophorectomy.
  • Transgender (trans) male affirmation: aids in gender dysphoria, prevention of future gynecologic problems, and transition to obtaining new legal gender documentation.[8]
  • Severe developmental disabilities: this treatment is controversial at best. In the United States, specific cases of sterilization due to developmental disabilities have been found by state-level Supreme Courts to violate the patient's constitutional and common-law rights.[9]
  • Postpartum: to remove either a severe case of placenta praevia (a placenta that has either formed over or inside the birth canal) or placenta percreta (a placenta that has grown into and through the wall of the uterus to attach itself to other organs), as well as a last resort in case of excessive obstetrical haemorrhage.[10]
  • Chronic pelvic pain: should try to obtain the pain etiology, although it may have no known cause.[11]
  • PMS and menstrual pain and other psychic and physical conditions caused by the menstrual period and causing suffering and diminishing life quality.

Risks and adverse effects

[edit]

In 1995, the short-term mortality (within 40 days of surgery) was reported at 0.38 cases per 1000 when performed for benign causes. Risks for surgical complications were the presence of fibroids, younger age (vascular pelvis with higher bleeding risk and larger uterus), dysfunctional uterine bleeding and parity.[12]

The mortality rate is several times higher when performed in patients who are pregnant, have cancer or other complications.[13]

The long-term effect on all case mortality is relatively small. Women under the age of 45 years have a significantly increased long-term mortality that is believed to be caused by the hormonal side effects of hysterectomy and prophylactic oophorectomy.[14][15] This effect is not limited to pre-menopausal women; even women who have already entered menopause were shown to have experienced a decrease in long-term survivability post-oophorectomy.[16]

Approximately 35% of women after hysterectomy undergo another related surgery within 2 years.[17]

Ureteral injury is not uncommon and occurs in 0.2 per 1,000 cases of vaginal hysterectomy and 1.3 per 1,000 cases of abdominal hysterectomy.[18] The injury usually occurs in the distal ureter close to the infundibulopelvic ligament or as a ureter crosses below the uterine artery, often from blind clamping and ligature placement to control hemorrhage.[19]

Recovery

[edit]

Hospital stay is 3 to 5 days or more for the abdominal procedure and between 1 and 2 days (but possibly longer) for vaginal or laparoscopically assisted vaginal procedures.[20] After the procedure, the American College of Obstetricians and Gynecologists recommends not inserting anything into the vagina for the first 6 weeks (including inserting tampons or having sex).[21]

Unintended oophorectomy and premature ovarian failure

[edit]

Removal of one or both ovaries is performed in a substantial number of hysterectomies that were intended to be ovary sparing.[22]

The average onset age of menopause after hysterectomy with ovarian conservation is 3.7 years earlier than average.[23] This has been suggested to be due to the disruption of blood supply to the ovaries after a hysterectomy or due to missing endocrine feedback of the uterus. The function of the remaining ovaries is significantly affected in about 40% of people, and some of them even require hormone replacement therapy. Surprisingly, a similar and only slightly weaker effect has been observed for endometrial ablation which is often considered as an alternative to hysterectomy.[24]

A substantial number of women develop benign ovarian cysts after a hysterectomy.[25]

Effects on sexual life and pelvic pain

[edit]

After hysterectomy for benign indications, the majority of patients report improvement in sexual life and pelvic pain. A smaller share of patients report worsening of their sexual life and other problems. The picture is significantly different for hysterectomy performed for malignant reasons; the procedure is often more radical with substantial side effects.[26][27] A proportion of patients who undergo a hysterectomy for chronic pelvic pain continue to have pelvic pain after a hysterectomy and develop dyspareunia (painful sexual intercourse).[28]

Premature menopause and its effects

[edit]

Hysterectomies that also include the surgical removal of the ovaries (i.e. an oophorectomy) result in significant hormonal changes to the body. Estrogen levels fall sharply when the ovaries are removed, removing the protective effects of estrogen on the cardiovascular and skeletal systems. This condition is often referred to as "surgical menopause", although it is substantially different from a naturally occurring menopausal state; the former is a sudden hormonal shock to the body that causes rapid onset of menopausal symptoms such as hot flashes, while the latter is a gradually occurring decrease of hormonal levels over a period of years with uterus intact and ovaries able to produce hormones even after the cessation of menstrual periods.[29]

One study showed that the risk of subsequent cardiovascular disease is substantially increased for women who had a hysterectomy at age 50 or younger. No association was found for women undergoing the procedure after age 50. The risk is higher when ovaries are removed, but still noticeable even when ovaries are preserved.[30]

Several other studies have found that osteoporosis (decrease in bone density) and increased risk of bone fractures are associated with hysterectomies.[31][32] This has been attributed to the modulatory effect of estrogen on calcium metabolism and the drop in serum estrogen levels after menopause can cause excessive loss of calcium leading to bone wasting.

Hysterectomies have also been linked with higher rates of heart disease and weakened bones. Those who have undergone a hysterectomy with both ovaries removed typically have reduced testosterone levels as compared to those left intact.[22] Reduced levels of testosterone in women are predictive of height loss, which may occur as a result of reduced bone density,[33] while increased testosterone levels in women are associated with a greater sense of sexual desire.[34]

Oophorectomy before the age of 45 is associated with a fivefold mortality from neurologic and mental disorders.[35]

Urinary incontinence and vaginal prolapse

[edit]

Urinary incontinence and vaginal prolapse are well known adverse effects that develop with high frequency a very long time after the surgery. Typically, those complications develop 10–20 years after the surgery.[36] For this reason exact numbers are not known, and risk factors are poorly understood. It is also unknown if the choice of surgical technique has any effect. It has been assessed that the risk for urinary incontinence is approximately doubled within 20 years after hysterectomy. One long-term study found a 2.4-fold increased risk for surgery to correct urinary stress incontinence following hysterectomy.[37][38]

The risk for vaginal prolapse depends on factors such as number of vaginal deliveries, the difficulty of those deliveries, and the type of labor.[39] Overall incidence is approximately doubled after hysterectomy.[40]

Adhesion formation and bowel obstruction

[edit]

The formation of postoperative adhesions is a particular risk after hysterectomy because of the extent of dissection involved as well as the fact the hysterectomy wound is in the most gravity-dependent part of the pelvis into which a loop of bowel may easily fall.[41] In one review, incidence of small bowel obstruction due to intestinal adhesion was found to be 15.6% in non-laparoscopic total abdominal hysterectomies vs. 0.0% in laparoscopic hysterectomies.[42]

Wound infection

[edit]

Wound infection occurs in approximately 3% of cases of abdominal hysterectomy. The risk is increased by obesity, diabetes, immunodeficiency disorder, use of systemic corticosteroids, smoking, wound hematoma, and preexisting infection such as chorioamnionitis and pelvic inflammatory disease.[43] Such wound infections mainly take the form of either incisional abscess or wound cellulitis. Typically, both confer erythema, but only an incisional abscess confers purulent drainage. The recommended treatment of an incisional abscess after hysterectomy is by incision and drainage, and then coverage by a thin layer of gauze followed by sterile dressing. The dressing should be changed and the wound irrigated with normal saline at least twice each day. In addition, it is recommended to administer an antibiotic active against staphylococci and streptococci, preferably vancomycin, when there is a risk of MRSA.[43] The wound can be allowed to close by secondary intention. Alternatively, if the infection is cleared and healthy granulation tissue is evident at the base of the wound, the edges of the incision may be reapproximated, such as by using butterfly stitches, staples or sutures.[43] Sexual intercourse remains possible after hysterectomy. Reconstructive surgery remains an option for women who have experienced benign and malignant conditions.[44] : 1020–1348 

Other rare problems

[edit]

Hysterectomy may cause an increased risk of the relatively rare renal cell carcinoma. The increased risk is particularly pronounced for young women; the risk was lower after vaginally performed hysterectomies.[45] Hormonal effects or injury of the ureter were considered as possible explanations.[46][47] In some cases, the renal cell carcinoma may be a manifestation of an undiagnosed hereditary leiomyomatosis and renal cell cancer syndrome.

Removal of the uterus without removing the ovaries can produce a situation that, on rare occasions, can result in ectopic pregnancy due to an undetected fertilization that had yet to descend into the uterus before surgery. Two cases have been identified and profiled in an issue of the Blackwell Journal of Obstetrics and Gynecology; over 20 other cases have been discussed in additional medical literature.[48] On very rare occasions, sexual intercourse after hysterectomy may cause a transvaginal evisceration of the small bowel.[49] The vaginal cuff is the uppermost region of the vagina that has been sutured closed. A rare complication, it can dehisce and allow the evisceration of the small bowel into the vagina.[50]

Alternatives

[edit]
Myomectomy
Sutured uterus wound after myomectomy

Depending on the indication, there are alternatives to hysterectomy:

Heavy bleeding

[edit]

Levonorgestrel intrauterine devices are highly effective at controlling dysfunctional uterine bleeding (DUB) or menorrhagia and should be considered before any surgery.[51]

Menorrhagia (heavy or abnormal menstrual bleeding) may also be treated with the less invasive endometrial ablation, which is an outpatient procedure in which the lining of the uterus is destroyed with heat, mechanically, or by radio frequency ablation.[52] Endometrial ablation greatly reduces or eliminates monthly bleeding in ninety percent of patients with DUB. It is not effective for patients with very thick uterine lining or uterine fibroids.[53]

Uterine fibroids

[edit]
Further information: Uterine fibroids

Levonorgestrel intrauterine devices are highly effective in limiting menstrual blood flow and improving other symptoms. Side effects are typically very moderate because the levonorgestrel (a progestin) is released in low concentration locally. There is now substantial evidence that Levonorgestrel-IUDs provide good symptomatic relief for women with fibroids.[54]

Uterine fibroids may be removed and the uterus reconstructed in a procedure called "myomectomy". A myomectomy may be performed through an open incision, laparoscopically, or through the vagina (hysteroscopy).[55]

Uterine artery embolization (UAE) is a minimally invasive procedure for treatment of uterine fibroids. Under local anesthesia, a catheter is introduced into the femoral artery at the groin and advanced under radiographic control into the uterine artery. A mass of microspheres or polyvinyl alcohol (PVA) material (an embolus) is injected into the uterine arteries to block the flow of blood through those vessels.[56] The restriction in blood supply usually results in a significant reduction of fibroids and improvement of heavy bleeding tendency. The 2012 Cochrane review comparing hysterectomy and UAE did not find any major advantage for either procedure. While the UAE procedure is associated with shorter hospital stay and a more rapid return to normal daily activities, it was also associated with a higher risk for minor complications later on. There were no differences between UAE and hysterectomy with regards to major complications.[57]

Uterine fibroids can be removed with a non-invasive procedure called Magnetic Resonance guided Focused Ultrasound (MRgFUS).

Uterine prolapse

[edit]

Prolapse may also be corrected surgically without removal of the uterus.[58] There are several strategies that can be utilized to help strengthen pelvic floor muscles and prevent the worsening of prolapse. These include, but are not limited to, use of "kegel exercises", vaginal pessary, constipation relief, weight management, and care when lifting heavy objects.[59]

Types

[edit]
Schematic drawing of types of hysterectomy

Hysterectomy, in the literal sense of the word, means merely the removal of the uterus. However, other organs such as the ovaries, fallopian tubes, and the cervix are very frequently removed as part of the surgery.[60]

  • Radical hysterectomy: complete removal of the uterus, cervix, upper vagina, and parametrium. Indicated for cancer. Lymph nodes, ovaries, and fallopian tubes are also usually removed in this situation, such as in Wertheim's hysterectomy.[61]
  • Total hysterectomy: complete removal of the uterus and cervix, with or without oophorectomy.
  • Subtotal hysterectomy: removal of the uterus, leaving the cervix in situ.

Subtotal (supracervical) hysterectomy was originally proposed with the expectation that it may improve sexual functioning after hysterectomy, it has been postulated that removing the cervix causes excessive neurologic and anatomic disruption, thus leading to vaginal shortening, vaginal vault prolapse, and vaginal cuff granulations.[62] These theoretical advantages were not confirmed in practice, but other advantages over total hysterectomy emerged. The principal disadvantage is that the risk of cervical cancer is not eliminated, and women may continue cyclical bleeding (although substantially less than before the surgery). These issues were addressed in a systematic review of total versus supracervical hysterectomy for benign gynecological conditions, which reported the following findings:[63]

  • There was no difference in the rates of incontinence, constipation, measures of sexual function, or alleviation of pre-surgery symptoms.
  • Length of surgery and amount of blood lost during surgery were significantly reduced during supracervical hysterectomy compared to total hysterectomy, but there was no difference in post-operative transfusion rates.[64]
  • Febrile morbidity was less likely and ongoing cyclic vaginal bleeding one year after surgery was more likely after supracervical hysterectomy.
  • There was no difference in the rates of other complications, recovery from surgery, or readmission rates.

In the short term, randomized trials have shown that cervical preservation or removal does not affect the rate of subsequent pelvic organ prolapse.[65]

Supracervical hysterectomy does not eliminate the possibility of having cervical cancer since the cervix itself is left intact and may be contraindicated in women with increased risk of this cancer; regular pap smears to check for cervical dysplasia or cancer are still needed.[66][67]

Technique

[edit]

Hysterectomy can be performed in different ways. The oldest known technique is vaginal hysterectomy. The first planned hysterectomy was performed by Konrad Johann Martin Langenbeck - Surgeon General of the Hannovarian army, although there are records of vaginal hysterectomy for prolapse going back as far as 50BC.[68]

The first abdominal hysterectomy recorded was by Ephraim McDowell. He performed the procedure in 1809 for a mother of five with a large ovarian mass on her kitchen table.[69]

In modern medicine today, laparoscopic vaginal (with additional instruments passing through ports in small abdominal incisions, close or in the navel) and total laparoscopic techniques have been developed.

Abdominal hysterectomy

[edit]

Most hysterectomies in the United States are done via laparotomy (abdominal incision, not to be confused with laparoscopy). A transverse (Pfannenstiel) incision is made through the abdominal wall, usually above the pubic bone, as close to the upper hair line of the individual's lower pelvis as possible, similar to the incision made for a caesarean section. This technique allows physicians the greatest access to the reproductive structures and is normally done for the removal of the entire reproductive complex.[70] The recovery time for an open hysterectomy is 4–6 weeks and sometimes longer due to the need to cut through the abdominal wall. Historically, the biggest problem with this technique was infections, but infection rates are well-controlled and not a major concern in modern medical practice. An open hysterectomy provides the most effective way to explore the abdominal cavity and perform complicated surgeries. Before the refinement of the vaginal and laparoscopic vaginal techniques, it was also the only possibility to achieve subtotal hysterectomy; meanwhile, the vaginal route is the preferable technique in most circumstances.[71][72]

Vaginal hysterectomy

[edit]

Vaginal hysterectomy is performed entirely through the vaginal canal and has clear advantages over abdominal surgery such as fewer complications, shorter hospital stays and shorter healing time.[73][74] Abdominal hysterectomy, the most common method, is used in cases such as after caesarean delivery, when the indication is cancer, when complications are expected, or when surgical exploration is required.

Laparoscopic-assisted vaginal hysterectomy

[edit]

With the development of laparoscopic techniques in the 1970s and 1980s, the "laparoscopic-assisted vaginal hysterectomy" (LAVH) has gained great popularity among gynecologists because compared with the abdominal procedure it is less invasive and the post-operative recovery is much faster. It also allows better exploration and slightly more complicated surgeries than the vaginal procedure. LAVH begins with laparoscopy and is completed such that the final removal of the uterus (with or without removing the ovaries) is via the vaginal canal. Thus, LAVH is also a total hysterectomy; the cervix is removed with the uterus.[75] If the cervix is removed along with the uterus, the upper portion of the vagina is sutured together and called the vaginal cuff.[76]

Laparoscopic-assisted supracervical hysterectomy

[edit]

The "laparoscopic-assisted supracervical hysterectomy" (LASH) was later developed to remove the uterus without removing the cervix using a morcellator which cuts the uterus into small pieces that can be removed from the abdominal cavity via the laparoscopic ports.[77]

Total laparoscopic hysterectomy

[edit]

Total laparoscopic hysterectomy (TLH) was developed in the early 90s by Prabhat K. Ahluwalia in Upstate New York.[78] TLH is performed solely through the laparoscopes in the abdomen, starting at the top of the uterus, typically with a uterine manipulator. The entire uterus is disconnected from its attachments using long, thin instruments through the "ports". Then, all the tissue to be removed is passed through the small abdominal incisions.

Other techniques

[edit]

Supracervical (subtotal) laparoscopic hysterectomy (LSH) is performed similarly to total laparoscopic surgery, but the uterus is amputated between the cervix and fundus.[79]

Dual-port laparoscopy is a form of laparoscopic surgery using two 5 mm midline incisions: the uterus is detached through the two ports and removed through the vagina.[80][81]

"Robotic hysterectomy" is a variant of laparoscopic surgery using special, remotely controlled instruments that allow the surgeon finer control as well as three-dimensional magnified vision.[82]

  • Uterus prior to hysterectomy
    Uterus prior to hysterectomy
  • Laparoscopical hysterectomy
    Laparoscopical hysterectomy
  • Cervical stump (white) after removal of the uterine corpus at laparoscopic supracervical hysterectomy
    Cervical stump (white) after removal of the uterine corpus at laparoscopic supracervical hysterectomy
  • Transvaginal extraction of the uterus in total laparoscopical hysterectomy
    Transvaginal extraction of the uterus in total laparoscopical hysterectomy
  • End of a laparoscopical hysterectomy
    End of a laparoscopical hysterectomy

Comparison of techniques

[edit]

Patient characteristics such as the reason for needing a hysterectomy, uterine size, descent of the uterus, presence of diseased tissues surrounding the uterus, previous surgery in the pelvic region, obesity, history of pregnancy, the possibility of endometriosis, or the need for an oophorectomy, will influence a surgeon's surgical approach when performing a hysterectomy.[83][needs update]

Vaginal hysterectomy is recommended over other variants where possible for women with benign diseases.[71][72][83] Vaginal hysterectomy was shown to be superior to LAVH and some types of laparoscopic surgery causing fewer short- and long-term complications, more favorable effect on sexual experience with shorter recovery times and fewer costs.[84][85][86]

Laparoscopic surgery offers certain advantages when vaginal surgery is not possible but also has the disadvantage of significantly longer time required for the surgery.[83][73]

In one 2004 study conducted in the UK comparing abdominal (laparotomic) and laparoscopic techniques, laparoscopic surgery was found to cause longer operation time and a higher rate of major complications while offering much quicker healing.[87] In another study conducted in 2014, laparoscopy was found to be "a safe alternative to laparotomy" in patients receiving total hysterectomy for endometrial cancer. Researchers concluded the procedure "offers markedly improved perioperative outcomes with a lower reoperation rate and fewer postoperative complications when the standard of care shifts from open surgery to laparoscopy in a university hospital".[88]

The abdominal technique is very often applied in difficult circumstances or when complications are expected. Given these circumstances, the complication rate and time required for surgery compares very favorably with other techniques; however time required for healing is much longer.[83]

Hysterectomy by abdominal laparotomy is correlated with a much higher incidence of intestinal adhesions than other techniques.[42]

Time required for completion of surgery in the eVAL trial is reported as follows:[87]

  • abdominal 55.2 minutes average, range 19–155
  • vaginal 46.6 minutes average, range 14–168
  • laparoscopic (all variants) 82.5 minutes average, range 10–325 (combined data from both trial arms)

Morcellation has been widely used especially in laparoscopic techniques and sometimes for the vaginal technique, but now appears to be associated with a considerable risk of spreading benign or malignant tumors.[89][90] In April 2014, the FDA issued a memo alerting medical practitioners to the risks of power morcellation.[91]

Robotic-assisted surgery is presently used in several countries for hysterectomies. Additional research is required to determine the benefits and risks involved, compared to conventional laparoscopic surgery.[92]

A 2014 Cochrane review found that robotic-assisted surgery may have a similar complication rate when compared to conventional laparoscopic surgery. In addition, there is evidence to suggest that although the surgery may take longer, robotic-assisted surgery may result in shorter hospital stays.[92] More research is necessary to determine if robotic-assisted hysterectomies are beneficial for people with cancer.[92]

Previously reported marginal advantages of robotic-assisted surgery could not be confirmed; only differences in hospital stay and cost remain statistically significant.[93][94][95] In addition, concerns over widespread misleading marketing claims have been raised.[96]

Summary—Advantages and disadvantages of different hysterectomy techniques
Technique Benefits Disadvantages
Abdominal hysterectomy
  • No limitation by the size of the uterus[83]
  • Combination with reduction and incontinence surgery possible[citation needed]
  • No increase in post-surgical complications compared with vaginal[83]
  • Longest recovery period and return to normal activities[83]
  • May have a higher risk of bleeding compared with laparoscopic surgery[83]
  • Vaginal or Laparoscopic technique preferred for people who are obese[97]
Vaginal hysterectomy
  • Shortest operation time[83]
  • Short recovery period and discharge from hospital[83]
  • Less pain medication and lower hospital costs compared with laparoscopic technique[83]
  • Lowest cost[83]
  • Limited by the size of the uterus and previous surgery[83]
  • Limited ability to evaluate the fallopian tubes and ovaries[98]
Laparoscopic supracervical hysterectomy (subtotal hysterectomy)
  • Unclear if subtotal approach leads to a reduction in pelvic organ prolapse in the long-term[99]
  • No evidence that this technique improves sexual function or reduces operative risk of urinary or bowel damage[99][100]
  • Faster return to normal activities[99]
  • Women must have regular cervical cancer screening following surgery[99][100]
  • Possibility of cyclical bleeding following subtotal approach[99]
Laparoscopic-assisted vaginal hysterectomy (LAVH)
  • Possible with a larger uterus, depending on the surgeon's skills[98]
  • Combination with reduction operations are possible[citation needed]
  • Higher cost than vaginal approach[98]
  • Malignancies can only be removed by this approach if they are intact[98]
  • Not suggested for people with cardiopulmonary disease[98]
Total laparoscopic hysterectomy
  • Short inpatient treatment duration compared with abdominal[83]
  • Allows the possibility to diagnose and treat other pelvic diseases[83][98]
  • Quicker return to normal activities compared with abdominal[83][98]
  • Less bleeding, fevers, infections compared with abdominal surgery[83]
  • Associated with a high quality of life in the long term, compared with abdominal[83]
  • Increased length of surgery[83]
  • Requires a high degree of laparoscopic surgical skills[83][98]
  • May have a higher risk of bladder or ureter injury[83]
Single-port laparoscopic hysterectomy / mini laparoscopic hysterectomy
  • Improved cosmetic outcomes compared with conventional laparoscopic hysterectomy[83]
  • More research required[83]
  • No significant clinical improvements compared with conventional laparoscopic hysterectomy[83]
Robotic-assisted hysterectomy
  • May result in shorter hospital stays[92]
  • More research required[92]
  • Similar complication rate compared with conventional laparoscopic[92][83]
  • Longer surgical times[92][83]
  • Increased cost[93]
  • More research required[92]

Incidence

[edit]

Canada

[edit]

In Canada, the number of hysterectomies between 2008 and 2009 was almost 47,000. The national rate for the same timeline was 338 per 100,000 population, down from 484 per 100,000 in 1997. The reasons for hysterectomies differed depending on whether the woman was living in an urban or rural location. Urban women opted for hysterectomies due to uterine fibroids and rural women had hysterectomies mostly for menstrual disorders.[101]

United States

[edit]

Hysterectomy is the second most common major surgery among women in the United States (the first is cesarean section). In the 1980s and 1990s, this statistic was the source of concern among some consumer rights groups and puzzlement among the medical community,[102] and brought about informed choice advocacy groups like Hysterectomy Educational Resources and Services (HERS) Foundation, founded by Nora W. Coffey in 1982.

According to the National Center for Health Statistics, of the 617,000 hysterectomies performed in 2004, 73% also involved the surgical removal of the ovaries. There are currently an estimated 22 million women in the United States who have undergone this procedure. Nearly 68 percent were performed for benign conditions such as endometriosis, irregular bleeding, and uterine fibroids.[1] Such rates being highest in the industrialized world has led to the controversy that hysterectomies are being largely performed for unwarranted reasons.[103] More recent data suggests that the number of hysterectomies performed has declined in every state in the United States. From 2010 to 2013, there were 12 percent fewer hysterectomies performed, and the types of hysterectomies were more minimally invasive in nature, reflected by a 17 percent increase in laparoscopic procedures.[104]

United Kingdom

[edit]

In the UK, 1 in 5 women is likely to have a hysterectomy by the age of 60, and ovaries are removed in about 20% of hysterectomies.[105]

Germany

[edit]

The number of hysterectomies in Germany has been constant for many years. In 2006, 149,456 hysterectomies were performed. Additionally, of these, 126,743 (84.8%) successfully benefited the patient without incident. Women between the ages of 40 and 49 accounted for 50 percent of hysterectomies, and those between the ages of 50 and 59 accounted for 20 percent.[106] In 2007, the number of hysterectomies decreased to 138,164.[64] In recent years, the technique of laparoscopic or laparoscopically assisted hysterectomies has been raised into the foreground.[107][108]

Denmark

[edit]

In Denmark, the number of hysterectomies from the 1980s to the 1990s decreased by 38 percent. In 1988, there were 173 such surgeries per 100,000 women, and by 1998, this number had been reduced to 107. The proportion of abdominal supracervical hysterectomies in the same period grew from 7.5 to 41 percent. A total of 67,096 women underwent hysterectomy during these years.[109]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Hysterectomy

View on Grokipedia
from Grokipedia
A hysterectomy is a surgical procedure entailing the excision of the uterus, either wholly or partially, primarily to alleviate symptoms from benign pathologies such as uterine leiomyomas (fibroids), endometriosis, adenomyosis, or dysfunctional uterine bleeding, and to manage malignant conditions including endometrial, cervical, or ovarian cancers. This intervention, one of the most prevalent gynecologic surgeries worldwide, renders the patient infertile and terminates menstrual cycles, though it does not precipitate menopause absent concomitant oophorectomy. In the United States, roughly 600,000 such operations occur annually, with prevalence among adult women approximating 17%, though incidence has waned owing to alternatives like uterine artery embolization or endometrial ablation for non-cancerous indications. Surgical variants encompass total hysterectomy (uterus and cervix), supracervical or partial (uterine corpus alone), and radical (incorporating parametria and upper vagina for oncologic purposes), executed via abdominal, vaginal, laparoscopic, or robotic routes to minimize morbidity. While efficacious for symptom relief, empirical evidence from cohort studies links hysterectomy—even ovary-sparing—to elevated long-term hazards including cardiovascular events, hypertension, stroke, metabolic syndrome, and accelerated physiological aging, underscoring imperatives for rigorous indication scrutiny and comprehensive risk disclosure.

History

Ancient and Pre-Modern Procedures

The earliest documented attempts at hysterectomy occurred in via the vaginal route, primarily for severe or inversion, though prior mentions in medical texts around 2000 years ago lack confirmatory evidence of execution. Themison of Athens reportedly conducted the first such procedure circa 50 BCE on a with a gangrenous prolapsed , involving direct vaginal extirpation without or hemostatic measures. Similarly, (c. 98–138 CE), a Greek physician practicing in , performed vaginal hysterectomies for inverted uteri, describing techniques that relied on traction and incision but yielded high mortality from uncontrolled , , and shock due to the absence of antisepsis or vascular ligation. These interventions were exceptional, reserved for life-threatening conditions, as the was viewed in Hippocratic and Galenic traditions as a mobile organ prone to displacement causing hysteria-like symptoms, yet surgical removal was deemed too hazardous for routine application. In the pre-modern era, spanning the medieval and early modern periods through the , vaginal hysterectomies remained sporadic and largely limited to cases of traumatic during or necrotic , with procedures entailing crude manual disarticulation or knifing through vaginal tissues. European and Islamic medical texts, such as those by 11th-century surgeon Albucasis (Abū al-Qāsim al-Zahrāwī), alluded to uterine surgeries but provided no verified hysterectomy successes, emphasizing conservative treatments like or pessaries instead. Survival rates were negligible, often below 10% in recorded attempts, attributable to from fecal contamination, exsanguination without clamps or ligatures, and postoperative exhaustion, rendering the operation a last-resort measure performed by midwives or barber-surgeons rather than formalized gynecology. Abdominal approaches were entirely precluded until the , as exposure invited fatal infections without Listerian principles. Overall, pre-modern hysterectomies exemplified the era's surgical constraints, prioritizing palliation over excision amid profound risks.

19th-Century Advancements

The first planned vaginal hysterectomy was performed by Conrad Langenbeck in , , in 1813, on a with ; the procedure involved prolapsing the and ligating vessels, though early vaginal approaches had been attempted sporadically since ancient times with limited success due to hemorrhage and infection risks. Abdominal hysterectomy emerged later in the century, with Charles Clay conducting the first recorded procedure in , , on November 17, 1843, for what was believed to be an ovarian fibroid but proved to be a misdiagnosis; the patient succumbed postoperatively, highlighting the era's challenges including uncontrolled bleeding and . Subsequent attempts in the 1840s and 1850s yielded variable outcomes, as surgeons like Ellis Burnham achieved the first successful abdominal hysterectomy in , in 1853, removing a while preserving the initially, though full extirpation remained perilous with mortality rates exceeding 70% in many series due to inadequate and lack of antisepsis. Vaginal techniques advanced concurrently, with Paul F. Eve performing the first documented successful vaginal hysterectomy in , around 1843 for inversion of the , yet overall survival hinged on case selection for benign conditions like rather than . Key enablers included the introduction of ether anesthesia in 1846, which facilitated longer intra-abdominal operations, and James Simpson's use of in 1847, reducing patient trauma during procedures. By mid-century, surgeons such as Nathan Bozeman and Washington L. Atlee refined ligation methods for ovarian vessels, improving in abdominal approaches, while Thomas Keith in reported over 100 vaginal hysterectomies by the 1870s with mortality dropping to around 10% through meticulous technique. Late-19th-century progress accelerated with Joseph Lister's antisepsis principles from 1867, which drastically curbed postoperative infections; Emil Freund standardized abdominal hysterectomy in the , emphasizing en bloc removal for fibroids and incorporating silver clamps for vessel control, contributing to mortality reductions below 20% in specialized centers by 1890. These advancements shifted hysterectomy from experimental desperation—often for uncontrollable uterine hemorrhage or large myomas—to a more viable intervention, though it remained controversial owing to ethical debates over elective removal in non-life-threatening cases and persistent risks compared to conservative therapies.

20th-Century Milestones and Modern Refinements

In the early , subtotal abdominal hysterectomy, which removes the uterine corpus while preserving the , remained the predominant technique due to technical challenges in safely excising the and concerns over postoperative complications. By the , total abdominal hysterectomy—encompassing removal of both the corpus and —superseded it, driven by evidence of reduced risk for cervical stump and advancements in surgical precision and . The discovery of antibiotics in the and maturation of techniques in the 1930s dramatically lowered infection and hemorrhage-related mortality, transforming hysterectomy from a high-risk procedure with rates exceeding 10% in the mid-19th century to safer operations with complication rates under 5% by mid-century. Laparoscopic approaches emerged in the late 1980s, with Harry Reich performing the first in 1988, followed by the inaugural total in 1989, enabling visualization and dissection through small incisions and reducing recovery times compared to open . Modern refinements emphasize minimally invasive methods, including laparoscopically assisted vaginal hysterectomy (LAVH) and robotic-assisted techniques, which leverage articulated instruments and enhanced optics for improved dexterity in complex cases, though evidence shows comparable outcomes to conventional with potentially higher costs. Vaginal natural orifice transluminal endoscopic (vNOTES), gaining traction since the 2010s, further minimizes scarring by accessing the transvaginally without abdominal ports.

Indications and Benefits

Benign Conditions

Hysterectomy serves as a definitive treatment for several benign gynecological conditions, particularly when symptoms severely impair and conservative therapies—such as hormonal medications, minimally invasive procedures, or —prove inadequate or unsuitable. In the United States, benign indications account for the majority of the approximately 500,000 to hysterectomies performed annually, with procedures increasingly favoring minimally invasive routes to reduce recovery time and complications. Common benign pathologies include uterine leiomyomas, , adenomyosis, , and , each involving distinct pathophysiological mechanisms leading to pain, hemorrhage, or structural failure. Uterine leiomyomas, or fibroids, represent the leading benign indication, comprising about 51% of cases. These benign tumors arise from proliferation in the , affecting up to 80% of women by age 50, with symptomatic growth causing , pelvic pressure, , or through distortion of the or vasculature compression. Hysterectomy is pursued when fibroids exceed 10-12 weeks' gestational size or fail response to alternatives like or myomectomy, providing complete resolution absent in conservative options. Abnormal uterine bleeding (AUB), often structural or ovulatory dysfunction-related, accounts for roughly 42% of benign hysterectomies and manifests as prolonged or excessive menses leading to hemoglobin levels below 10 g/dL in severe instances. Guidelines recommend hysterectomy only after exhausting medical management with progestins, tranexamic acid, or endometrial ablation, as it eliminates the dysfunctional endometrium but forfeits fertility. Adenomyosis, characterized by ectopic endometrial glands invading the , induces diffuse uterine enlargement and ; hysterectomy offers curative removal of the affected organ, as partial treatments like intrauterine devices provide only symptomatic palliation. , involving extrauterine endometrial implants causing adhesions and chronic inflammation, prompts hysterectomy in refractory deep infiltrating disease, though ovarian preservation may leave residual ovarian endometriomas risking symptom recurrence. Pelvic organ prolapse, including uterine descent due to ligamentous laxity from childbirth trauma or collagen defects, necessitates hysterectomy when the uterus protrudes beyond the introitus (stage III-IV), often combined with vault suspension to avert enterocele formation. While uterine-sparing pessary or sacrohysteropexy exist, hysterectomy facilitates direct apical repair in postmenopausal women not desiring fertility preservation.

Malignant and Precancerous Conditions

Hysterectomy serves as the cornerstone of surgical management for , particularly in stages I and II, where total hysterectomy with bilateral salpingo-oophorectomy enables both therapeutic removal and pathological staging to assess myometrial invasion and involvement. For cases with cervical stromal invasion, radical hysterectomy extends resection to include parametrial tissues, upper , and pelvic , improving locoregional control in early disease. In advanced stages, hysterectomy may follow neoadjuvant chemotherapy if residual pelvic disease persists, though systemic therapy predominates. For cervical cancer confined to the cervix (stages IA2 to IB3 per FIGO classification), radical hysterectomy with pelvic lymphadenectomy remains the standard for operable cases, removing the uterus, cervix, parametria, and upper vagina to achieve negative margins and reduce recurrence risk. Simple hysterectomy suffices for microinvasive lesions (IA1 with lymphovascular invasion) or select low-risk early-stage tumors, preserving more anatomy while effectively treating disease. Recent data indicate a shift toward open abdominal approaches over minimally invasive radical hysterectomy due to higher recurrence rates observed in laparoscopic or robotic series, prompting guideline updates favoring traditional surgery for optimal oncologic outcomes. In epithelial , hysterectomy forms part of comprehensive staging and , routinely including total hysterectomy, bilateral salpingo-oophorectomy, and omentectomy to excise macroscopic disease and evaluate peritoneal spread, with studies confirming its role in initial management regardless of uterine involvement. For tumors limited to one in young patients desiring preservation, unilateral salpingo-oophorectomy may suffice without hysterectomy, but bilateral involvement or advanced disease necessitates full uterine removal alongside adnexectomy. Precancerous conditions warrant hysterectomy when conservative measures fail or risk of progression is high, such as in atypical endometrial hyperplasia or unresponsive to progestin therapy, where total hysterectomy provides definitive cure and histopathological confirmation, averting up to 40% progression to endometrioid adenocarcinoma. For high-grade (CIN 3), simple hysterectomy is indicated in women who have completed childbearing, especially with gland involvement or unsatisfactory , eliminating persistent lesions that carry a 12-30% risk of invasive if untreated.

Emergency and Other Indications

Emergency peripartum hysterectomy (EPH) is performed to address life-threatening obstetric hemorrhage, typically within 24 hours of delivery, when conservative measures such as uterotonics, , or fail. The primary indications include , which accounts for approximately 29% of cases, abnormal placentation such as disorders (up to 73% in some series), and (around 45%). These procedures carry high maternal morbidity, with hysterectomy rates for severe postpartum hemorrhage varying from 0.2 to 2.6 per 1,000 deliveries globally, influenced by factors like cesarean delivery rates and access to blood products. Cesarean hysterectomies predominate over those following due to increased risks of atony and accreta in surgical births. Non-obstetric emergencies requiring hysterectomy are rarer and include uncontrollable hemorrhage from ruptured ectopic pregnancies or traumatic uterine injury, though these often involve organ-preserving alternatives first. In such scenarios, total abdominal hysterectomy may be , but data emphasize rapid multidisciplinary intervention to minimize , as maternal mortality can reach 4-12% in EPH cohorts despite intervention. Beyond emergent contexts, hysterectomy serves prophylactic roles in women with hereditary nonpolyposis colorectal cancer (Lynch syndrome), where it, combined with bilateral salpingo-oophorectomy, reduces endometrial and ovarian cancer risks by eliminating susceptible tissue. This approach is recommended after childbearing for mutation carriers, given lifetime endometrial cancer risks exceeding 40% without surgery. Hysterectomy is also conducted for individuals with , particularly males seeking alignment with male physiology, often alongside to halt menstrual cycles and production. Guidelines from organizations like the World Professional Association for Health deem it medically necessary after and , though long-term outcomes data remain limited, with primary diagnoses for such procedures frequently citing rather than comorbid benign pathology. on causal efficacy for dysphoria resolution is derived largely from self-reported satisfaction, with potential confounders including in cohorts.

Surgical Techniques

Classification by Extent of Removal

Hysterectomies are classified primarily by the extent of removal of the and adjacent structures, with the main types being subtotal (supracervical), total, and radical. This classification determines the surgical scope, potential preservation of anatomical function, and associated risks such as the need for ongoing in subtotal cases. The choice depends on the underlying , with subtotal and total procedures typically used for benign conditions and radical for malignancies. Subtotal or supracervical hysterectomy entails excision of the uterine corpus (body) while leaving the intact, often including removal of the fallopian tubes but preserving the ovaries unless separately indicated. This preserves the endocervical canal and may reduce operative time and blood loss in select cases, though evidence from randomized trials shows no significant long-term benefits in urinary, bowel, or compared to total hysterectomy, and it necessitates continued screening due to retained risk. Total hysterectomy involves complete removal of the , including the corpus and , typically with closure of the . It is the most common variant, performed in approximately 90% of cases for benign indications, eliminating the need for future while addressing symptoms like heavy bleeding or fibroids without preserving potentially problematic cervical tissue. or may accompany it but is not inherent to the uterine extent. Radical hysterectomy extends beyond the to include the , upper one-third to half of the , parametrial tissues, and often pelvic nodes, classified further by systems such as Piver-Rutledge (types I-IV based on parametrial and vaginal resection depth). Reserved for cervical or endometrial cancers, it aims for oncologic clearance but carries higher risks of urinary and due to autonomic nerve disruption; type III (moderate radicality) remains standard for early-stage disease per guidelines.

Open Abdominal Hysterectomy

Open abdominal hysterectomy, also known as total abdominal hysterectomy when the is removed, is a surgical procedure that removes the through a large incision in the lower , allowing direct visualization and access to the . This approach is typically performed under general and lasts 1-2 hours. It is indicated primarily for benign conditions such as uterine fibroids, , , or , particularly when the is enlarged beyond 12 weeks' gestational size, severe adhesions from prior surgeries exist, or extrauterine pathology like adnexal masses requires exploration. For malignant conditions, it facilitates staging and resection in cases where minimally invasive routes are infeasible or intraoperative conversion from occurs. Contraindications include advanced beyond stage IB, where chemoradiation is preferred over . The procedure begins with a incision, usually low transverse (Pfannenstiel) for better or vertical midline for extensive access. The is entered, adhesions lysed if present, and the bowel packed superiorly. Round are clamped, divided, and ligated bilaterally to enter the broad ligament spaces. The is reflected inferiorly, exposing the uterine vessels, which are skeletonized, clamped, and ligated. If salpingo-oophorectomy is planned, ovarian vessels are divided. Cardinal and uterosacral ligaments are clamped and divided, followed by circumferential clamping of the , amputation of the uterus, and closure of the with absorbable sutures. The pelvis is irrigated, confirmed, and the closed in layers. Compared to minimally invasive alternatives like , open abdominal hysterectomy offers advantages in managing complex or large specimens but incurs disadvantages including longer operative times in some scenarios, increased blood loss (average 400 mL), higher rates of wound infections, and extended recovery periods of 4-6 weeks or more. Patients typically require a 1-2 day stay, with full recovery taking 6 weeks, during which heavy lifting and sexual activity are restricted to minimize dehiscence risk. Specific risks include urinary tract injuries (e.g., ureteral or damage in 1-2% of cases), bowel , dehiscence, , and pelvic infections, with overall complication rates higher than vaginal or laparoscopic routes due to the open incision. Evidence from guidelines emphasizes reserving this technique for situations where safer alternatives cannot ensure complete resection or adequate inspection.

Vaginal Hysterectomy

Vaginal hysterectomy involves the removal of the through an incision made in the upper , without requiring an abdominal incision. This approach is particularly suitable for cases involving , smaller uteri (typically weighing less than 280 grams), or benign conditions such as fibroids that do not distort pelvic anatomy. It is recommended as the preferred route for benign disease whenever feasible due to its association with reduced morbidity compared to abdominal hysterectomy. The procedure begins with the patient under general or regional , positioned in dorsal . An incision is made in the posterior to access the , which is then clamped, cut, and ligated from surrounding ligaments, including the and uterosacral ligaments, while carefully dissecting the from the lower uterine segment. The is detached from the and removed through the vaginal canal; the is closed with absorbable sutures. Concomitant procedures, such as anterior/posterior for repair, can be performed. The success rate exceeds 95% in appropriately selected patients, with operative times averaging 60-90 minutes. Advantages include shorter stays (typically 1-2 days), reduced postoperative pain, lower rates, and faster recovery of 2-4 weeks compared to the 4-6 weeks or more for abdominal hysterectomy. Randomized trials demonstrate that vaginal hysterectomy results in less blood loss (mean 200-300 mL), fewer febrile episodes, and lower costs, with no difference in major complication rates when compared to laparoscopic approaches in select cases. In a randomized with abdominal hysterectomy for enlarged uteri, vaginal approach shortened hospital stay by one day and reduced overall costs without increasing complications. Contraindications include large or adherent uteri, significant adhesions from prior surgeries, suspected requiring staging, or narrow vaginal access that limits visualization. Relative limitations involve difficulty with adnexal removal, succeeding in only 65-97.5% of cases. Complications, occurring in 5-10% of cases, encompass urinary tract injury (1-2%, primarily ), vaginal cuff dehiscence (less than 1%), and hemorrhage, though rates are lower than abdominal methods due to avoidance of . Long-term risks include vaginal shortening or in 5-10% of patients. Evidence from meta-analyses confirms vaginal hysterectomy's superior perioperative outcomes, including reduced hospital stay and quicker return to work, supporting its prioritization over more invasive routes.

Minimally Invasive Approaches

Minimally invasive approaches to hysterectomy utilize techniques, involving small abdominal incisions for inserting a camera and instruments, avoiding large open incisions (sometimes using laser). These methods include total hysterectomy (TLH), where the entire is removed and extracted laparoscopically or vaginally; -assisted vaginal hysterectomy (LAVH), combining for initial dissection with vaginal removal; and supracervical hysterectomy (LSH), preserving the . In TLH, ports are placed in the , the is detached from surrounding structures using laparoscopic tools, vessels are sealed, and the specimen is morcellated or extracted via the or mini-incision. LAVH facilitates visualization of adhesions or large uteri, transitioning to vaginal completion, while LSH reduces operative time by avoiding full uterine removal. These approaches enable same-day or short-stay procedures for benign indications, with studies reporting hospital stays of 1-2 days compared to 3-5 for abdominal hysterectomy. Laparoscopic or vaginal methods typically allow recovery in 2-4 weeks, shorter than the 4-6 weeks or more for traditional open abdominal hysterectomy. These advantages are particularly beneficial for elderly patients, as videolaparoscopic hysterectomy is less invasive, offering quicker recovery and lower risk of complications compared to traditional methods. For benign conditions, evidence from randomized controlled trials and meta-analyses shows laparoscopic methods yield less (mean 100-200 mL vs. 300-500 mL in open), reduced postoperative pain, and faster return to activity (2-4 weeks vs. 4-6 weeks). Operative times may be longer (120-180 minutes vs. 90-120 for open) but complication rates are comparable or lower, including fewer wound infections. Conversion to open occurs in 1-5% of cases due to adhesions or . In early-stage , randomized trials indicate minimally invasive radical hysterectomy associates with higher recurrence rates (e.g., 4-year disease-free survival 82% vs. 96% for open) and possibly worse overall survival, attributed to potential tumor spillage or effects, leading to recommendations favoring open approaches for . For , laparoscopic staging and hysterectomy show equivalent oncologic outcomes to open with better perioperative recovery. Risks specific to these techniques include port-site hernias (0.5-2%), urinary tract injuries (1-2%, similar to open), and vaginal cuff dehiscence (1-4%, higher with energy devices). Patient selection is critical; , prior surgeries, or large fibroids increase technical difficulty. Long-term data confirm reduced formation compared to open .

Robotic-Assisted and Emerging Techniques

Robotic-assisted hysterectomy employs systems such as the , which provides surgeons with three-dimensional visualization, tremor filtration, and articulated instruments for enhanced precision during minimally invasive procedures. First approved by the FDA for gynecologic use in 2005, this approach has been applied to both benign and malignant indications, facilitating procedures like total hysterectomy with salpingo-oophorectomy through small abdominal incisions. Operative times typically range from 120 to 240 minutes, longer than conventional due to setup and docking requirements, but studies report reduced blood loss (median 50-100 mL) and hospital stays (1-2 days) compared to open surgery. Comparative analyses indicate no significant differences in major complications, readmission rates, or long-term outcomes between robotic-assisted and conventional laparoscopic hysterectomy for benign conditions, with robotic methods incurring higher costs (up to $2,000-3,000 more per case) without proportional benefits in conversion rates or postoperative pain. A 2024 of randomized trials confirmed equivalent surgical and patient-reported outcomes, attributing robotic adoption partly to shorter learning curves for complex cases, such as those involving or adhesions, where conversion to open surgery drops below 5%. For malignant indications, robotic approaches yield similar oncologic to , with blood loss under 200 mL and yields exceeding 15 per procedure, though from high-quality trials remains limited by surgeon experience variability. Emerging techniques build on minimally invasive principles, including vaginal natural orifice transluminal endoscopic (vNOTES), introduced clinically around 2012 and gaining traction post-2020 for its scarless access via the vaginal route. vNOTES enables hysterectomy with uterine weights up to 500 g, reporting operative times of 60-90 minutes, negligible blood loss (<50 mL), and same-day discharge in over 80% of cases, with complication rates under 2% in initial series; it avoids abdominal trocars, reducing port-site hernias. Single-port robotic systems, such as the da Vinci SP approved in 2018, further advance this by consolidating instruments into one incision, achieving low pain scores (VAS <3) and complication rates below 1% in early 2024 studies of benign hysterectomies. Other innovations like mini-laparoscopy (using 2-3 mm ports) show promise for reduced tissue trauma but lack large-scale outcome data beyond pilot feasibility trials. These methods prioritize outpatient feasibility and cosmesis, though long-term comparative effectiveness trials are ongoing to validate advantages over established laparoscopy.

Risks and Complications

Perioperative and Immediate Risks

Perioperative risks of hysterectomy encompass intraoperative events such as hemorrhage and organ injury, as well as immediate postoperative issues including infection and thromboembolism. Overall 30-day postoperative complication rates range from 4.4% to 6.2% across surgical approaches, with abdominal hysterectomy associated with higher composite rates (10.3%) compared to laparoscopic (5.3%) or vaginal (6.8%). Major complications, defined as those requiring intervention or prolonging hospital stay, occur in approximately 4.4% of laparoscopic cases and 4.9% of abdominal procedures. Intraoperative bleeding is a primary concern, contributing to up to half of gynecological postoperative complications, though severe hemorrhage remains rare with median rates below 1%. Organ injuries, particularly to the genitourinary tract (e.g., bladder or ureter) or gastrointestinal tract (e.g., bowel), occur in 0.1-1% of cases, with ureteral injury rates around 0.02-1.4% depending on approach and surgeon experience. These injuries often arise from dissection near pelvic structures and may necessitate immediate repair or conversion to open surgery. Immediate postoperative anemia, resulting from surgical blood loss, can cause symptoms such as dyspnea (shortness of breath), fatigue, and weakness due to reduced oxygen delivery to tissues. Infections, including wound, urinary tract, or pelvic abscesses, affect 4-25% of patients, with higher rates (6-25%) in abdominal hysterectomy versus 4-10% in vaginal approaches. Urinary tract infections are the most frequent, occurring in up to 3.9% of cases. Venous thromboembolism, including deep vein thrombosis or pulmonary embolism, represents another acute risk, with incidence influenced by prophylaxis protocols and patient factors like obesity. Anesthesia-related complications, such as respiratory issues or cardiovascular events, are less common but elevated in patients with comorbidities. Risk mitigation involves preoperative optimization, antibiotic prophylaxis, and thromboprophylaxis, which reduce infection and clot rates per guidelines from bodies like the American College of Obstetricians and Gynecologists (ACOG). ACOG strongly recommends antibiotic prophylaxis for all hysterectomies to lower infection risk, with regimens varying by procedure type (abdominal, vaginal, laparoscopic), patient factors (obesity, diabetes), or institutional protocols, administered preoperatively, intraoperatively, or postoperatively. Patient-specific factors, including body mass index and surgical route, modulate these risks, with minimally invasive techniques generally lowering overall perioperative morbidity.

Long-Term Health Impacts

Hysterectomy, particularly when accompanied by bilateral salpingo-oophorectomy (BSO), is associated with elevated risks of cardiovascular disease (CVD), including coronary heart disease (CHD) and stroke, even in cases of ovarian conservation. A 2024 meta-analysis of observational studies found that hysterectomy increased the relative risk of CVD by approximately 1.17 (95% CI: 1.09-1.26), CHD by 1.20 (95% CI: 1.06-1.35), and stroke by 1.23 (95% CI: 1.08-1.40), though it did not significantly elevate all-cause or cardiovascular mortality. These risks may stem from disruptions to ovarian blood supply, accelerated ovarian aging, or inflammatory responses, with hazard ratios for CVD reaching 1.09 after hysterectomy alone and 1.19 with BSO. Hysterectomy is associated with an increased risk of type 2 diabetes, particularly when combined with bilateral oophorectomy, likely due to hormonal changes and premature menopause. Multiple studies confirm this association, with risks elevated by 13-40% depending on ovarian conservation. There is no evidence linking hysterectomy to an increased risk of type 1 diabetes, an autoimmune condition typically diagnosed earlier in life. Skeletal health deteriorates post-hysterectomy, with heightened incidence of osteoporosis and fractures independent of oophorectomy status. A systematic review indicated that hysterectomy elevates fracture risk (OR 1.56-2.37 across studies) and reduces bone mineral density (BMD) at lumbar spine and hip sites, attributed to potential alterations in pelvic vascularization or hormonal microenvironments despite preserved ovaries. Population-based cohorts report a 1.5- to 2-fold increase in osteoporosis diagnosis and fracture events among hysterectomized women followed for over a decade, with premenopausal procedures showing greater BMD loss (up to 5-10% at 2 years) compared to intact controls. Pelvic floor disorders, including urinary incontinence and prolapse, persist or emerge long-term after hysterectomy due to denervation and structural support loss. Hysterectomy correlates with a 1.5- to 2-fold higher likelihood of stress urinary incontinence within 10 years, escalating to pelvic organ prolapse (OR 1.56; 95% CI: 1.35-1.78) beyond that duration in meta-analyzed cohorts. Vaginal and abdominal approaches show comparable risks, with prospective data confirming sustained pelvic symptoms in 20-30% of women at 5-10 years post-surgery. Sexual function outcomes vary, with systematic reviews reporting no overall decline in desire, arousal, or satisfaction for most women, though subsets experience dyspareunia or lubrication issues from vaginal shortening or nerve disruption. A 2023 meta-analysis of 22 studies (n>5,000) found neutral effects on composite scores (SMD 0.05; 95% CI: -0.12 to 0.22) across surgical routes, yet qualitative data highlight persistent dysfunction in 10-20% due to psychological factors or anatomical changes. Oncologic profiles shift post-hysterectomy with BSO, reducing ovarian and incidence (HR 0.4-0.7) but elevating risk (HR 1.4-1.8), potentially from hormonal imbalances or alterations. All-cause mortality remains comparable to non-hysterectomized peers when ovaries are conserved before age 50, though BSO before natural shortens lifespan by 1-2 years via CVD and cancer pathways. Comprehensive reviews emphasize individualized , as procedure extent modulates these effects.

Psychological and Quality-of-Life Effects

Hysterectomy for benign conditions is associated with improvements in symptoms of depression and anxiety, as well as overall (QoL), in many patients, particularly when performed to alleviate severe gynecological symptoms such as heavy bleeding or from fibroids. A of 22 studies involving 5,978 participants found significant reductions in depression scores post-hysterectomy, alongside enhanced vitality, reduced discomfort, and better sexual activity metrics both short- and long-term. These benefits are attributed to the resolution of underlying , with minimally invasive approaches yielding superior short-term QoL gains compared to open abdominal methods, including better physical functioning and bodily pain control. However, evidence indicates elevated long-term risks of de novo depression and anxiety following hysterectomy, even with ovarian conservation, with absolute risk increases of 6.6% for depression and 4.7% for anxiety over 30 years, particularly among women undergoing the procedure before age 45. This risk escalates with bilateral oophorectomy, which induces surgical and hormonal disruptions contributing to mood disorders, as opposed to natural menopause. Some studies report higher postoperative depressive symptoms, such as diminished interest or persistent low mood, especially in younger patients or those without ovarian preservation. Decisional regret occurs in a minority of cases but is more prevalent among younger women, with rates of surgical regret reaching 32.5% in those aged 30 or younger versus 9.1% in older groups, often tied to loss. Overall regret for the procedure itself remains low at approximately 2.8%, with over 95% of patients affirming their decision when adequately counseled preoperatively; however, 21-43% express persistent regret over three years post-surgery. -related regret may intensify initially but often diminishes over time for most, though it persists in a subset, underscoring the need for thorough preoperative discussions on reproductive implications. Sexual function and body image exhibit mixed outcomes, with some meta-analyses noting preserved or improved and due to pain relief, while others highlight potential declines in genital sensation from nerve disruption, leading to or reduced satisfaction in up to certain subgroups. Psychological interventions post-surgery can mitigate pelvic floor-related distress and enhance coping, reducing anxiety prevalence from baseline levels. Conflicting findings across studies may reflect selection biases in patient cohorts or variations in surgical extent, with pre-existing conditions predicting poorer trajectories. Long-term QoL improvements are more consistent in postmenopausal women, where anxiety and perceptions tend to stabilize or enhance post-procedure.

Alternatives

Pharmacological and Conservative Options

Pharmacological interventions for uterine fibroids primarily target hormonal pathways to reduce symptoms such as heavy bleeding and , though evidence for long-term efficacy remains limited. GnRH agonists and antagonists, including elagolix, suppress ovarian production, leading to fibroid shrinkage of up to 50% in volume within three to six months, but their use is typically short-term (up to six months) due to side effects like loss and menopausal symptoms. Selective modulators (SPRMs), such as , have demonstrated reductions in fibroid volume by 20-40% and improved quality of life in randomized trials, yet concerns over rare liver have prompted regulatory restrictions in some regions. Progestins, including oral or injectable forms, offer symptom by stabilizing the but do not consistently reduce fibroid size. For (menorrhagia), often a primary indication for hysterectomy consideration, first-line medical options include , an that reduces blood loss by 30-60% during menses with minimal side effects in short-term use, supported by Cochrane reviews as superior to . Levonorgestrel-releasing intrauterine systems (LNG-IUS) achieve amenorrhea in up to 50% of users after one year by providing local progestin, outperforming oral progestins in reducing bleeding volume per Cochrane analyses, though expulsion rates reach 5-10%. Combined oral contraceptives and nonsteroidal anti-inflammatory drugs (NSAIDs) provide moderate relief (20-40% blood loss reduction) but are less effective for structural causes like fibroids. In and , where hysterectomy may be proposed for refractory pain or bleeding, hormonal suppression remains the cornerstone. NSAIDs alleviate acutely, while GnRH analogs reduce lesion size and pain scores by 40-70% in trials, albeit with hypoestrogenic risks necessitating add-back therapy. Progestins, particularly LNG-IUS for , yield sustained symptom improvement in 60-80% of cases over 12-24 months, with prospective studies favoring it over oral alternatives for bleeding control. Aromatase inhibitors show preliminary promise for pain reduction in but lack robust safety data for extended use. Conservative management emphasizes symptom monitoring and lifestyle modifications when pathology is mild or asymptomatic, avoiding intervention unless quality of life is impaired. Regular exercise and weight management correlate with reduced bleeding severity, though causal evidence is observational and confounded by selection bias. Watchful waiting is appropriate for small fibroids under 5 cm without symptoms, with serial ultrasound monitoring every 6-12 months to track growth rates averaging 1-2 mm per year. Non-pharmacologic adjuncts like acupuncture yield inconsistent pain relief in small trials for endometriosis, insufficient for recommendation over evidence-based therapies. Overall, these options delay or obviate surgery in 40-70% of cases depending on condition severity, per systematic reviews, but failure rates necessitate timely reassessment.

Uterine-Preserving Surgical Interventions

Uterine-preserving surgical interventions address symptomatic benign uterine conditions, including leiomyomas (fibroids), abnormal uterine bleeding, and pelvic organ prolapse, without requiring hysterectomy. These procedures prioritize symptom relief, fertility preservation, and uterine retention, often yielding comparable short-term outcomes to hysterectomy but with potential for recurrence or reintervention. Selection depends on patient age, desire for future pregnancy, fibroid characteristics, and prolapse severity, with evidence from randomized trials supporting their efficacy in appropriately selected cases. Myomectomy, the excision of intramural or subserosal fibroids while conserving the , serves as the primary surgical option for women with symptomatic leiomyomas seeking . Performed via open abdominal, laparoscopic, or robotic approaches, laparoscopic myomectomy reduces blood loss and postoperative pain compared to abdominal methods, with operative times averaging 100-150 minutes for multiple fibroids. Health-related improves significantly post-procedure, though scores may lag slightly behind those after hysterectomy at one year; long-term fibroid recurrence approaches 22% over 11 years, necessitating reintervention in about 11% of cases. Myomectomy outperforms in fibroid-related at two years and is preferred for pregnancy-desiring patients due to lower risks. Endometrial ablation or resection targets by destroying the endometrial lining via thermal, radiofrequency, or electrosurgical methods, often under hysteroscopic guidance. This outpatient procedure achieves amenorrhea or oligomenorrhea in 40-60% of patients, with satisfaction rates exceeding 80% at , and offers shorter recovery (days versus weeks) and fewer complications than hysterectomy. However, up to 25% of women may require hysterectomy within five years due to treatment failure or persistent symptoms, particularly in those with large uteri or ; hysterectomy provides superior long-term bleeding control but at higher perioperative risk. Uterine artery embolization (UAE), a catheter-based intervention, occludes fibroid blood supply using embolic particles, inducing ischemia and volume reduction of 30-50% within six months. Symptom improvement occurs in over 85% of patients, with sustained quality-of-life gains observed in observational studies up to five years; technical success exceeds 95%, though post-embolization affects most patients transiently. UAE yields lower rates and higher risks than myomectomy, limiting its use in fertility-focused cases, and meta-analyses confirm comparable efficacy to myomectomy for symptom control but with fewer major complications. For , preservation techniques like sacrohysteropexy or uterosacral ligament suspension use mesh or native tissue to restore anatomy laparoscopically or vaginally, avoiding hysterectomy. A 2024 meta-analysis reports lower recurrence (10-15% versus 20% with hysterectomy) and complication rates, with faster return to normal activity; uterine preservation maintains and avoids vaginal shortening risks associated with or hysterectomy. These approaches suit women rejecting hysterectomy for cultural, , or menopausal status reasons, though long-term durability data remain limited beyond five years.

Management of Specific Conditions

Uterine Fibroids
Hysterectomy serves as a definitive treatment for symptomatic uterine leiomyomas when conservative options such as medication or myomectomy fail to alleviate , pain, or pressure symptoms. Symptomatic fibroids account for approximately 51.4% of benign hysterectomies, with the procedure eliminating fibroid-related symptoms in nearly all cases due to complete removal of the . The choice of approach—vaginal, laparoscopic, or abdominal—depends on fibroid size, number, and uterine mobility, with vaginal hysterectomy preferred for smaller uteri to minimize complications and recovery time. Abnormal Uterine Bleeding
For nonpregnant reproductive-aged women with acute or chronic unresponsive to hormonal or nonhormonal medical therapies, hysterectomy provides definitive control by eliminating the source of bleeding. This indication represents about 41.7% of benign hysterectomies, often linked to ovulatory dysfunction or without atypia. In cases with atypical hyperplasia, hysterectomy is prioritized to prevent progression to , with total hysterectomy ensuring removal of at-risk tissue. Adenomyosis
Hysterectomy is the definitive management for in women past childbearing age who experience persistent heavy bleeding, , or despite medical treatments like NSAIDs or hormonal therapies. is identified in up to 42% of hysterectomies performed for , frequently coexisting with fibroids and contributing to diffuse uterine enlargement. Total hysterectomy addresses the condition's intrauterine pathology comprehensively, though conservative surgical alternatives like excision may be considered in select cases to preserve . Endometriosis
In severe refractory to excision, medical suppression, or conservative , —often with bilateral salpingo-oophorectomy—relieves symptoms such as and by removing estrogen-dependent lesions, though extrauterine may persist. Guidelines recommend this approach for women not seeking preservation, with ovarian conservation possible if ovaries are unaffected to avoid surgical . Total hysterectomy outperforms subtotal in reducing recurrence for -associated , based on comparative outcomes in symptom resolution. Pelvic Organ Prolapse
Hysterectomy combined with vaginal vault suspension is indicated for symptomatic , particularly when conservative measures like pessaries fail, to restore pelvic anatomy and alleviate bulge or pressure sensations. Vaginal hysterectomy facilitates concurrent prolapse repair via uterosacral or sacrospinous fixation, offering lower morbidity than abdominal routes for stage II or higher . Uterine-preserving procedures like hysteropexy may suffice if or uterine retention is desired, but hysterectomy is standard when coexisting conditions such as bleeding warrant uterine removal. Gynecologic Malignancies
For early-stage , standard management involves total hysterectomy with bilateral salpingo-oophorectomy and staging, achieving cure rates exceeding 90% in low-risk cases through minimally invasive approaches when feasible. In stage IA , radical hysterectomy removes the , , and parametria, serving as primary with adjuvant for high-risk features. These oncologic hysterectomies prioritize complete resection margins over benign techniques, with preoperative guiding extent of .

Epidemiology

Global and Historical Rates

In the United States, age-standardized hysterectomy incidence rates increased from 2.4 per 1,000 women in 1935 to a peak of 10.6 per 1,000 by 1975, driven by expanded surgical access for benign conditions such as uterine fibroids and abnormal bleeding. Rates subsequently declined due to the adoption of conservative treatments and minimally invasive alternatives, with projections estimating a further drop to 3.9 per 1,000 by 2035. By 2021, the age-adjusted prevalence among women aged 18 and older stood at 14.6%, reflecting cumulative historical procedures tempered by recent reductions in incidence. European rates followed a similar historical trajectory but at lower overall levels, with age-standardized annual incidences ranging from 173 per 100,000 women in Denmark to 295 per 100,000 in as of the early . Across European countries, crude rates for females decreased from 212.2 per 100,000 in 2010 to 174.7 per 100,000 in 2021, consistent with broader shifts toward non-surgical management of gynecologic conditions. In , total hysterectomy rates fell from 335.97 per 100,000 women in 2005 to 168.99 per 100,000 in 2019, with steeper declines for benign indications. Comprehensive global incidence data remain limited due to variations in reporting and healthcare systems, but rates are generally lower in low- and middle-income countries outside emergency contexts like peripartum hemorrhage, where incidences exceed those in high-income settings. In high-income regions, lifetime prevalence has historically approached 20-25% for women over 50, though recent cohorts show stabilization or decline amid evidence of procedure overuse for non-cancerous conditions. These patterns underscore a transition from mid-20th-century expansion to contemporary restraint, influenced by empirical outcomes data favoring preservation of reproductive organs when feasible.

Regional Variations and Disparities

Hysterectomy rates for benign conditions vary substantially across countries, influenced by healthcare practices, diagnostic thresholds, and access to alternatives. Among nations, age-standardized rates per 100,000 women ranged from 134 in to 283 in in data from the mid-2010s, with reporting one of the lowest at 173. In the United States, approximately 600,000 procedures occur annually, though population-based rates have declined to around 200-300 per 100,000 women in recent decades, exceeding many European counterparts like but aligning closer to at 295. reported 303 per 100,000 in 2017, reflecting a similar downward trend from prior highs. These differences persist despite comparable , potentially stemming from variations in conservative management adoption and surgical thresholds rather than underlying disease prevalence. Within the , geographic disparities are pronounced, with lifetime hysterectomy at 16.9% in the and 15.5% in the Midwest, compared to lower rates in the Northeast and West. Rural women exhibit higher than urban counterparts, at rates implying elevated procedure utilization possibly due to limited access to minimally invasive options or alternative therapies. Racial and ethnic disparities compound these patterns: undergo hysterectomies at higher rates than White women, with county-level analyses linking this to lower , where procedure rates elevate regardless of race but disparities widen in economically disadvantaged areas. and women are also 1.4-2 times more likely to receive abdominal hysterectomy over minimally invasive routes for benign indications, even after adjusting for comorbidities and , attributable to factors like hospital-level practices and provider biases rather than patient refusal. Socioeconomic gradients further drive disparities, as or Medicare recipients and those in lower- brackets face reduced access to laparoscopic or vaginal approaches, resulting in higher open surgery rates and associated complications. In , inter-country variations mirror these, with higher rates in and versus Nordic nations, though intra-regional data on race or disparities remain less documented due to uniform systems mitigating some access barriers. Globally, developing regions report elevated peripartum hysterectomies from obstetric emergencies, contrasting benign-focused rates in high-income areas. , hysterectomy among women aged 40 years and older declined from 2006 to 2016, with the largest decreases observed among non-Hispanic (from 11.5% to 9.8%) and women (from 7.2% to 5.9%). This trend reflects broader shifts away from hysterectomy for benign conditions, influenced by expanded uterine-preserving alternatives such as and , alongside heightened awareness of long-term risks like and . Despite the decline, procedural volumes for benign hysterectomies increased from 2015 to 2021, potentially driven by an aging population and improved access to minimally invasive techniques that reduce recovery time and complications. Surgical approaches have evolved toward minimally invasive (MIS), with MIS hysterectomy rates surpassing 50% among women aged 30–54 by 2020, varying by region but generally rising due to advancements in and that enable outpatient procedures. Vaginal hysterectomy, once preferred for its lower morbidity, has declined sharply—to under 10% in some U.S. and European settings by 2023—and is projected to comprise fewer than 8% of cases by 2030, as laparoscopic and robotic methods gain favor for their precision despite higher costs. Outpatient hysterectomies for conditions like rose from 2.6% in 2008 to 43.9% in 2015, reflecting enhanced perioperative protocols and economic pressures favoring . Sociodemographic factors exert significant influence on contemporary rates, with lower levels associated with higher hysterectomy incidence, including premenopausal procedures and younger age at surgery ( 1.5–2.0 for less than high school vs. education). Non-Hispanic face elevated odds (adjusted OR 1.4), alongside predictors like coverage, current , and Southern U.S. residence, where county-level socioeconomic deprivation correlates more strongly with rates than healthcare access metrics. Globally, patterns mirror these disparities, with higher peripartum hysterectomy rates in developing regions due to obstetric complications, while high-income areas show stabilization or decline amid guideline shifts prioritizing conservative management for fibroids and heavy bleeding.

Controversies

Claims of Overuse and Unnecessary Procedures

Claims of overuse of hysterectomies for benign conditions have persisted since the late , with critics arguing that the procedure is frequently recommended despite viable alternatives such as pharmacological therapies, , , or myomectomy. In the United States, where approximately 600,000 hysterectomies are performed annually, the majority address non-cancerous issues like uterine fibroids, , and , yet regional variations in rates—ranging from 124 to 286 per 10,000 women in some states—suggest inconsistent application of evidence-based necessity criteria rather than proportional disease prevalence. A 2014 analysis of over 300,000 U.S. hysterectomies for benign indications found that 18.7% were deemed inappropriate under established guidelines, with nearly 40% of patients not offered conservative treatments beforehand, including medications or less invasive procedures. Similarly, appropriateness evaluations have estimated overutilization rates between 16% and 70%, particularly when hormonal therapies or diagnostic evaluations for conditions like menorrhagia are skipped, leading to surgical intervention without exhausting stepwise management. For uterine fibroids, which account for up to 60% of hysterectomies, a 2024 study revealed that nearly 60% of patients underwent the procedure without prior less invasive options, despite evidence that alternatives like myomectomy or can effectively manage symptoms in many cases without uterine removal. In developing regions like , claims of overuse are amplified by socioeconomic factors, with prevalence rates exceeding 8% in states such as and , often linked to unindicated procedures among undereducated, low-income women for symptoms like heavy bleeding that could be addressed conservatively. These patterns highlight potential financial incentives in private clinics and inadequate , though U.S. trends show declining rates—from 27 per 10,000 inpatient procedures in earlier decades to about 15 by 2018—attributable to wider adoption of alternatives, underscoring that while overuse persists, it is not uniformly inevitable given advancing non-surgical options.

Evidence on Long-Term Outcomes and Necessity

Hysterectomy, particularly when performed for benign conditions, has been associated with increased long-term risks of , even with ovarian conservation. A 2023 of over 113,000 women found that hysterectomy alone raised the composite risk of cardiovascular events by 9%, with hazard ratios of 1.09 (95% CI, 1.06-1.12) for overall CVD and higher for (HR 1.14, 95% CI, 1.07-1.22). Similarly, a 2023 analysis linked early hysterectomy-induced to elevated CVD risks, including (adjusted HR 1.64, 95% CI, 1.18-2.29). These findings align with a 2019 review indicating heightened metabolic and cardiovascular morbidity post-procedure, independent of . When bilateral salpingo-oophorectomy (BSO) accompanies hysterectomy, risks extend to premature ovarian insufficiency, , , and all-cause mortality. A 2023 and of 37 studies reported that hysterectomy with BSO in premenopausal women increased risk (HR 1.62, 95% CI 1.39-1.90), (HR 1.60, 95% CI 1.16-2.20), and /parkinsonism, while reducing incidence. The same analysis noted decreased risk (HR 0.78, 95% CI 0.67-0.91) but emphasized net adverse effects on and due to hormonal deficits. A 2021 NIH corroborated these outcomes, highlighting elevated needs for further surgeries and early even without BSO. Evidence on necessity reveals patterns of overuse for non-malignant indications, where alternatives like myomectomy or suffice. A 2015 study estimated 18% of U.S. hysterectomies as potentially unnecessary, with 40% of eligible women not offered conservative options. For uterine fibroids—the leading benign reason—approximately 90% of procedures occur outside cancer contexts, despite low lifetime risk (under 1%) and effective non-surgical interventions. Long-term quality-of-life data show symptom relief in many cases but persistent regret in 6-43% over fertility loss, alongside declines in and . Decisional post-hysterectomy averages low (under 10% at one year), yet prospective tracking indicates worsening in subsets, particularly younger women facing endocrine disruptions. A 2023 analysis of premenopausal cases found improved sexual satisfaction short-term but no mitigation of broader morbidity, underscoring that necessity hinges on exhaustive trialing of uterus-preserving therapies for conditions like or . Socioeconomic disparities amplify overuse, with higher rates among less-educated women, suggesting procedural biases over evidence-based thresholds. Overall, empirical data prioritize hysterectomy for or refractory life-threatening bleeding, while cautioning against routine application given causal links to accelerated aging and chronic .

Socioeconomic and Policy Debates

Socioeconomic disparities in hysterectomy rates persist, with women of lower and levels experiencing higher . According to 2021 U.S. data, 18.4% of women with family incomes below 100% of the federal level had undergone hysterectomy, compared to 12.9% among those with incomes at or above 400% of the level. Similarly, is elevated among those with less than a high school (20.1%) versus college graduates (10.5%). These patterns hold across studies, indicating that lower correlates with increased likelihood of the procedure, potentially due to limited access to conservative treatments or diagnostic alternatives. Racial and ethnic variations compound these trends, with facing higher rates overall and greater disparities in procedure type. Hysterectomy rates are elevated in counties with lower , irrespective of race, but racial gaps widen in higher-poverty areas, where undergo the procedure at rates up to twice those of white women. Black and Medicaid-insured patients are less likely to receive minimally invasive hysterectomies, with odds 38% higher for abdominal approaches among after adjusting for confounders. Such disparities may stem from barriers in surgical volume, surgeon expertise, or systemic access issues rather than clinical necessity alone. Policy debates center on overuse for benign conditions, with U.S. rates historically exceeding those in other nations, prompting calls for stricter appropriateness criteria. Insurers have long contested excessive procedures, estimating in the early that many hysterectomies lacked sufficient justification, fueling discussions on pre-authorization and second opinions to curb volume. Recent analyses highlight geographic variation and potential financial incentives in models as drivers, with hospitals showing wide disparities in rates that exceed clinical explanations. Advocates argue for promoting alternatives like , which reduce costs and complications, yet policy reforms lag amid debates over balancing patient autonomy with evidence-based thresholds. Economic burdens amplify these concerns, as hysterectomy costs vary by route and setting, imposing hardships especially on lower-income groups. Mean total costs range from $31,934 for vaginal to $49,526 for robotic approaches, with annual U.S. direct expenditures estimated at $0.78–3.5 billion plus lost productivity. Post-procedure financial hardship affects 16.2% of recipients versus 13.6% of women overall, linked to recovery time and complications. Medicare coverage applies for medically necessary cases, but out-of-pocket shares (e.g., ~$1,853 for outpatient total hysterectomy) underscore access inequities. Controversies also encompass sterilization policies, where hysterectomies have been alleged in coercive contexts, echoing historical eugenics programs targeting marginalized groups. In the U.S., mid-20th-century forced sterilizations affected over 60,000, often via hysterectomy or tubal ligation on low-income or minority women, justified under public health pretexts but later deemed unethical. Recent claims, such as 2020 whistleblower reports of elevated hysterectomy rates at an ICE detention facility (affecting ~20% of detainees per allegations), raised coerced procedure concerns, though investigations found insufficient evidence of systemic policy endorsement. These incidents highlight ongoing tensions between reproductive autonomy and institutional practices, with policy responses emphasizing consent protocols amid skepticism toward unverified media narratives.

References

  1. https://www.acog.org/womens-health/faqs/hysterectomy
  2. https://www.ncbi.nlm.nih.gov/books/NBK564366/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC2926674/
  4. https://www.ncbi.nlm.nih.gov/books/NBK525761/
  5. https://emedicine.medscape.com/article/267273-overview
  6. https://www.cdc.gov/nchs/products/databriefs/db494.htm
  7. https://my.clevelandclinic.org/health/procedures/hysterectomy
  8. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/06/choosing-the-route-of-hysterectomy-for-benign-disease
  9. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805939
  10. https://www.heart.org/en/news/2023/12/01/ovary-sparing-hysterectomy-may-not-offer-protection-against-metabolic-syndrome
  11. https://pubmed.ncbi.nlm.nih.gov/34830617/
  12. https://www.dovepress.com/association-between-hysterectomy-and-accelerated-aging-protective-effe-peer-reviewed-fulltext-article-IJWH
  13. https://pubmed.ncbi.nlm.nih.gov/15985249/
  14. https://www.ogmagazine.org.au/21/3-21/hysterectomy-four-approaches/
  15. https://pubmed.ncbi.nlm.nih.gov/9155933/
  16. https://www.utmbhealth.com/services/ob-gyn/services/robotic-surgery/hysterectomy
  17. https://jtgga.org/articles/hysterectomy-a-comprehensive-surgical-approach/jtgga.2017.0097
  18. https://pubmed.ncbi.nlm.nih.gov/22519184/
  19. https://obgynkey.com/the-evolution-of-uterine-surgery-and-hysterectomy/
  20. https://www.jaypeedigital.com/eReader/chapter/9789351521792/ch1
  21. https://embryo.asu.edu/pages/hysterectomy
  22. https://www.aorn.org/article/19th-century--the-birth-of-surgery
  23. https://www.sciencedirect.com/science/article/abs/pii/S1553465010001172
  24. https://www.oxfordwomenshealth.co.nz/news/hysterectomy-then-and-now.html
  25. https://www.sciencedirect.com/science/article/abs/pii/S1521693404001816
  26. http://www.reneparejaginecologooncologo.com/images/ANZGOG/Rad_hyst_HISTORY_Polat-.pdf
  27. https://journals.lww.com/clinicalobgyn/Fulltext/2006/12000/The_Evolution_of_Uterine_Surgery.4.aspx?generateEpub=Article%257Cclinicalobgyn:2006:12000:00004%257C10.1097/01.grf.0000211945.51712.99%257C
  28. https://www.gfmer.ch/Books/Endoscopy_book/Ch15_hyster_lap.htm
  29. https://emedicine.medscape.com/article/1839957-overview
  30. https://www.acog.org/education-and-events/simulations/scog017/module
  31. https://www.sciencedirect.com/science/article/pii/S1048891X24191384
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC4985519/
  33. https://gpm.amegroups.org/article/view/10206/html
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC6247381/
  35. https://www.aafp.org/pubs/afp/issues/2014/0615/p987.html
  36. https://www.hopkinsmedicine.org/health/conditions-and-diseases/adenomyosis
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC5635831/
  38. https://my.clevelandclinic.org/health/diseases/16030-uterine-prolapse
  39. https://www.cancer.org/cancer/types/endometrial-cancer/treating/surgery.html
  40. https://www.mskcc.org/cancer-care/types/uterine-endometrial/treatment/surgery
  41. https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/hysterectomy-for-womb-cancer
  42. https://www.cancer.org/cancer/types/cervical-cancer/treating/surgery.html
  43. https://www.cancer.gov/news-events/cancer-currents-blog/2024/cervical-cancer-simple-hysterectomy
  44. https://www.mdanderson.org/cancerwise/cervical-cancer-treatment-minimally-invasive-radical-hysterectomy-vs-abdominal-hysterectomy.h00-159228090.html
  45. https://www.sciencedirect.com/science/article/pii/S1048891X24089242
  46. https://www.cancer.org/cancer/types/ovarian-cancer/treating/surgery.html
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC3800154/
  48. https://www.uptodate.com/contents/peripartum-hysterectomy-for-management-of-hemorrhage
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC3234143/
  50. https://www.sciencedirect.com/science/article/pii/S2405844025019929
  51. https://journals.lww.com/greenjournal/fulltext/2023/01000/incidence%2C_indications%2C_risk_factors%2C_and_outcomes.6.aspx
  52. https://www.sciencedirect.com/science/article/abs/pii/S0002937804001644
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC7757309/
  54. https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-021-03797-3
  55. https://www.nejm.org/doi/full/10.1056/NEJMoa052627
  56. https://pubmed.ncbi.nlm.nih.gov/24120286/
  57. https://pubmed.ncbi.nlm.nih.gov/38145751/
  58. https://www.sciencedirect.com/science/article/pii/S1553465023010221
  59. https://journals.lww.com/greenjournal/abstract/2017/05001/hysterectomy_as_gender_affirmation_surgery_in.622.aspx
  60. https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/hysterectomy
  61. https://teachmeobgyn.com/operations-procedures/gynaecology/hysterectomy/
  62. https://journals.lww.com/greenjournal/fulltext/2004/03000/a_randomized_comparison_of_total_or_supracervical.37.aspx
  63. https://www.mayoclinic.org/tests-procedures/abdominal-hysterectomy/multimedia/types-of-hysterectomy-surgery/img-20007786
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC4197497/
  65. https://stanfordhealthcare.org/medical-treatments/h/hysterectomy/types.html
  66. https://www.mayoclinic.org/tests-procedures/abdominal-hysterectomy/about/pac-20384559
  67. https://www.ncbi.nlm.nih.gov/books/NBK554482/
  68. https://emedicine.medscape.com/article/1839938-overview
  69. https://www.mayoclinic.org/tests-procedures/vaginal-hysterectomy/about/pac-20384541
  70. https://www.ajog.org/article/S0002-9378%2802%2900471-4/abstract
  71. https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-019-0784-4
  72. https://www.sciencedirect.com/science/article/abs/pii/S0020729203002716
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC11532236/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC3939153/
  75. https://www.sciencedirect.com/science/article/pii/S2468784724000825
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC10615228/
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC6591934/
  78. https://www.ajog.org/article/S0002-9378%2808%2901051-X/fulltext
  79. https://gynecolsurg.springeropen.com/articles/10.1186/s10397-019-1057-9
  80. https://www.nejm.org/doi/full/10.1056/NEJMoa1806395
  81. https://jamanetwork.com/journals/jamaoncology/fullarticle/2766807
  82. https://gpm.amegroups.org/article/view/10785/html
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC5367602/
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC3236390/
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC10678826/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC9691378/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC11321512/
  88. https://pubmed.ncbi.nlm.nih.gov/24914631/
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC8035818/
  90. https://pubmed.ncbi.nlm.nih.gov/24703710/
  91. https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/aogs.15099
  92. https://www.solutionhealth.org/2021/11/04/new-innovative-procedure-for-hysterectomies-now-performed-at-southern-nh-medical-center/
  93. https://pubmed.ncbi.nlm.nih.gov/38479382/
  94. https://www.ajog.org/article/S0002-9378%2824%2900316-8/fulltext
  95. https://www.sciencedirect.com/science/article/abs/pii/S0301211525009121
  96. https://www.mdpi.com/journal/jcm/special_issues/07YIW0MUH8
  97. https://pubmed.ncbi.nlm.nih.gov/23635631/
  98. https://gpm.amegroups.org/article/view/9138/html
  99. https://www.cmaj.ca/content/194/38/e1306
  100. https://www.intechopen.com/chapters/79921
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC9812207/
  102. https://www.verywellhealth.com/anemia-after-surgery-3156852
  103. https://www.uspharmacist.com/article/complications-of-hysterectomy
  104. https://www.ajog.org/article/S0002-9378%2816%2900055-7/fulltext
  105. https://www.emdocs.net/hysterectomy-complications/
  106. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2018/06/prevention-of-infection-after-gynecologic-procedures
  107. https://academic.oup.com/humrep/article/26/6/1512/2914011
  108. https://pubmed.ncbi.nlm.nih.gov/38747094/
  109. https://www.ahajournals.org/doi/10.1161/STROKEAHA.121.037305
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC5411675/
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC7850756/
  112. https://academic.oup.com/ejendo/article/193/3/S15/8239986
  113. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0243037
  114. https://pubmed.ncbi.nlm.nih.gov/7784026/
  115. https://www.ajog.org/article/S0002-9378%2825%2900164-4/abstract
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC8967811/
  117. https://academic.oup.com/jsm/article/20/4/447/7059565
  118. https://www.ajog.org/article/S0002-9378%2823%2900441-6/fulltext
  119. https://www.obgproject.com/2018/10/30/does-a-hysterectomy-before-50-shorten-lifespan/
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC8622061/
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC11192439/
  122. https://pubmed.ncbi.nlm.nih.gov/32623252/
  123. https://newsnetwork.mayoclinic.org/discussion/study-finds-women-at-greater-risk-of-depression-anxiety-after-hysterectomy/
  124. https://pmc.ncbi.nlm.nih.gov/articles/PMC7089568/
  125. https://pmc.ncbi.nlm.nih.gov/articles/PMC6210125/
  126. https://www.nature.com/articles/s41598-023-36838-2
  127. https://pubmed.ncbi.nlm.nih.gov/39601703/
  128. https://www.sciencedirect.com/science/article/abs/pii/S1701216319307327
  129. https://www.ajog.org/article/S0002-9378%2805%2901391-8/fulltext
  130. https://pmc.ncbi.nlm.nih.gov/articles/PMC7644126/
  131. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.878815/full
  132. https://www.liebertpub.com/doi/full/10.1089/WHR.2023.0045
  133. https://www.ginekologiaipoloznictwo.com/articles/assessment-of-quality-of-life-and-psychological-impact-of-hysterectomy-in-postmenopausal-women-a-prospective-cohort-stud.pdf
  134. https://pubmed.ncbi.nlm.nih.gov/26919185/
  135. https://pmc.ncbi.nlm.nih.gov/articles/PMC4212375/
  136. https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.70497
  137. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013180.pub2/abstract
  138. https://www.sciencedirect.com/science/article/pii/S2475037924000785
  139. https://pmc.ncbi.nlm.nih.gov/articles/PMC6142441/
  140. https://pmc.ncbi.nlm.nih.gov/articles/PMC4728737/
  141. https://www.mayoclinic.org/diseases-conditions/endometriosis/diagnosis-treatment/drc-20354661
  142. https://www.hopkinsmedicine.org/health/conditions-and-diseases/endometriosis
  143. https://www.mdpi.com/2077-0383/13/11/3302
  144. https://www.aafp.org/pubs/afp/issues/2022/0100/p33.html
  145. https://pubmed.ncbi.nlm.nih.gov/37837497/
  146. https://www.mayoclinic.org/diseases-conditions/uterine-fibroids/diagnosis-treatment/drc-20354294
  147. https://www.woosterhospital.org/what-are-my-non-surgical-endometriosis-treatment-options/
  148. https://www.nejm.org/doi/full/10.1056/NEJMoa1914735
  149. https://pubmed.ncbi.nlm.nih.gov/39428029/
  150. https://pubmed.ncbi.nlm.nih.gov/32192594/
  151. https://pmc.ncbi.nlm.nih.gov/articles/PMC12254167/
  152. https://pubmed.ncbi.nlm.nih.gov/31463964/
  153. https://pmc.ncbi.nlm.nih.gov/articles/PMC6713886/
  154. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2819%2931790-8/fulltext
  155. https://www.nature.com/articles/s41598-024-69754-0
  156. https://acquaintpublications.com/article/management_of_fibroids_for_patients_desiring_pregnancy_uae_uterine_artery_embolization_versus_myomectomy_a_review_of_the_literature
  157. https://www.contemporaryobgyn.net/view/uterine-preserving-surgery-offers-safe-effective-alternative-for-pop
  158. https://www.ajog.org/article/S0002-9378%2824%2901079-2/fulltext
  159. https://pmc.ncbi.nlm.nih.gov/articles/PMC5031283/
  160. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2013/04/management-of-acute-abnormal-uterine-bleeding-in-nonpregnant-reproductive-aged-women
  161. https://pmc.ncbi.nlm.nih.gov/articles/PMC9206934/
  162. https://www.sciencedirect.com/science/article/pii/S1521693424000531
  163. https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-021-01545-5
  164. https://www.aafp.org/pubs/afp/issues/2011/0101/p84.html
  165. https://pmc.ncbi.nlm.nih.gov/articles/PMC10253360/
  166. https://www.acog.org/womens-health/faqs/surgery-for-pelvic-organ-prolapse
  167. https://pubmed.ncbi.nlm.nih.gov/24145362/
  168. https://journals.lww.com/greenjournal/fulltext/2017/04000/practice_bulletin_no__176_summary__pelvic_organ.38.aspx
  169. https://www.cancer.gov/types/uterine/hp/endometrial-treatment-pdq
  170. https://pmc.ncbi.nlm.nih.gov/articles/PMC6554021/
  171. https://www.cancer.org/cancer/types/endometrial-cancer/treating/by-stage.html
  172. https://pmc.ncbi.nlm.nih.gov/articles/PMC8723888/
  173. https://journals.lww.com/mgmj/fulltext/2021/08040/hysterectomy__rates_and_routes_controversies.1.aspx
  174. https://www.valueinhealthjournal.com/article/S1098-3015%2824%2901853-9/fulltext
  175. https://www.nature.com/articles/s41598-024-66019-8
  176. https://worldpopulationreview.com/country-rankings/hysterectomy-rates-by-country
  177. https://pmc.ncbi.nlm.nih.gov/articles/PMC9529796/
  178. https://pmc.ncbi.nlm.nih.gov/articles/PMC8180274/
  179. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/ajo.13478
  180. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0233082
  181. https://www.sciencedirect.com/science/article/abs/pii/S1751721417300246
  182. https://www.jogc.com/article/S1701-2163%2819%2930818-7/fulltext
  183. https://pmc.ncbi.nlm.nih.gov/articles/PMC10593101/
  184. https://www.cdc.gov/nchs/data/databriefs/db494.pdf
  185. https://academyhealth.org/blog/2021-09/hysterectomy-rates-differ-race-and-geography-greater-racial-disparities-tied-county-socioeconomic-status
  186. https://www.scientificarchives.com/article/racial-disparities-in-surgical-outcomes-for-uterine-fibroids-a-systematic-review
  187. https://pmc.ncbi.nlm.nih.gov/articles/PMC7062558/
  188. https://www.jmig.org/article/S1553-4650%2824%2900302-9/abstract
  189. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2757249
  190. https://pubmed.ncbi.nlm.nih.gov/28840507/
  191. https://www.ajog.org/article/S0002-9378%2817%2930927-4/fulltext
  192. https://pmc.ncbi.nlm.nih.gov/articles/PMC11220048/
  193. https://www.ajog.org/article/S0002-9378%2822%2900482-3/abstract
  194. https://pubmed.ncbi.nlm.nih.gov/40306551/
  195. https://www.sciencedirect.com/science/article/pii/S0301211523006942?dgcid=rss_sd_all&
  196. https://pubmed.ncbi.nlm.nih.gov/40403305/
  197. https://www.sciencedirect.com/science/article/pii/S1048891X24023338
  198. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.14959
  199. https://pmc.ncbi.nlm.nih.gov/articles/PMC6177230/
  200. https://pubmed.ncbi.nlm.nih.gov/9048505/
  201. http://www.washington.edu/alumni/partnerships/publichealth/201008/vaezy.html
  202. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/j.1600-0412.2011.01309.x
  203. https://pubmed.ncbi.nlm.nih.gov/25542564/
  204. https://www.medscape.com/viewarticle/837829
  205. https://pubmed.ncbi.nlm.nih.gov/38179386/
  206. https://pubmed.ncbi.nlm.nih.gov/31852688/
  207. https://ihpi.umich.edu/news/plotting-downward-trend-traditional-hysterectomy
  208. https://www.mayoclinic.org/medical-professionals/obstetrics-gynecology/news/hysterectomy-associated-with-an-increased-risk-of-cardiovascular-disease-study-says/mac-20476157
  209. https://pubmed.ncbi.nlm.nih.gov/37364803/
  210. https://www.medicalnewstoday.com/articles/287736
  211. https://lowninstitute.org/guest-post-the-madness-of-unnecessary-hysterectomy-has-to-stop/
  212. https://pmc.ncbi.nlm.nih.gov/articles/PMC10765271/
  213. https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/ijgo.14400
  214. https://theconversation.com/hysterectomy-is-more-common-and-occurs-at-younger-ages-for-women-with-less-education-237937
  215. https://pubmed.ncbi.nlm.nih.gov/8417592/
  216. https://www.mdedge.com/obgyn/article/243103/hysterectomy/socioeconomic-disparities-persist-hysterectomy-access
  217. https://www.latimes.com/archives/la-xpm-1991-01-01-vw-7555-story.html
  218. https://www.qualityhealth.org/bree/wp-content/uploads/sites/8/2018/01/Hysterectomy-Final-Report-2018.pdf
  219. https://lowninstitute.org/video-hysterectomy-overuse-in-us-hospitals/
  220. https://pmc.ncbi.nlm.nih.gov/articles/PMC3558885/
  221. https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-022-07644-9
  222. https://www.sciencedirect.com/science/article/abs/pii/S1877575624000740
  223. https://www.medicare.org/articles/does-medicare-cover-a-hysterectomy/
  224. https://www.pbs.org/independentlens/blog/unwanted-sterilization-and-eugenics-programs-in-the-united-states/
  225. https://www.cnn.com/2020/09/16/us/ice-hysterectomy-forced-sterilization-history
  226. https://www.aclu.org/news/immigrants-rights/immigration-detention-and-coerced-sterilization-history-tragically-repeats-itself
  227. https://www.brennancenter.org/our-work/analysis-opinion/forced-sterilization-accusations-ice-facility-fit-trumps-poor-treatment
Add your contribution
Related Hubs
User Avatar
No comments yet.